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The most direct approach to elucidating the roles of 
herpes simplex virus (HSV) proteins in the viral repli­
cative cycle has been to isolate temperature-sensitive, 
cytolysis-resistant, and drug-resistant mutants that ex­
hibit alterations in the synthesis or activity of these 
proteins. 
The development of procedures for the introduction of 
temperature-sensitive mutations into physically defined 
regions of the viral genome and for fine mapping of 
these mutations has proven especially valuable. Thus, 
(1) hydroxylamine mutagenesis of the HSV-l BglII I 
fragment (coordinates 0.312-0.415) has facilitated the 
genetic and functional characterization of the gene for 
the major viral DNA -binding protein of 130 K molecular 
weight; (2) the selection of a mutant conditionally able 
to render infected cells resistant to immune cytolysis has 
led to identification of an HSV gene involved in the 
processing of viral glycoproteins; and (3) the combined 
use of temperature-sensitive and drug-resistant mutants 
has led to a better definition of the physical limits and 
functional domains of the gene for HSV DNA poly­
merase. 
The DNAs of herpes simplex virus types 1 and 2 (HSV-l and 
HSV -2) are sufficiently large to encode 50,000 amino acids 
corresponding to 70-80 polypeptides with an average molecular 
weight of 85,000 daltons [IJ. This calculation is clearly an 
underestimate of the total number of viral polypeptides gener­
ated during infection, however, since more than 200 polypep­
tides comprising primary gene products, processive intermedi­
ates, and mature products have been observed by two-dimen­
sional gel electrophoresis [2J. Although considerable progress 
has been made in mapping viral transcripts and polypeptides 
on the HSV -1 genome, specific functions have been assigned 
to fewer than 10 viral polypeptides. The most direct approach 
to elucidating the roles of viral proteins in the replicative 
process has been to isolate mutants that exhibit alterations in 
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the synthesis or activity of these proteins. To date, mutants 
have been derived from at least 6 strains of HSV -1 and 3 strains 
of HSV-2. Most have been derived by "brute force" mutagene­
sis, and the great majority of mutants currently available are 
conditional lethal mutants of the temperature-sensitive (ts) 
variety. A variety of mutants in nonessential genes, such as the 
genes responsible for syncytia (syn) formation and the HSV­
specific thymidine kinase (TK) gene, has also been identified. 
Complementation analysis of ts mutants from 10 laboratories 
has led to the identification of 33 essential cistrons of HSV-1 
and 20 essential cistrons of HSV-2 ([3J and unpublished obser­
vations). 
PROPERTIES OF HSV DNA 
Before undertaking a description of the genetics of HSV, a 
brief review of the properties of HSV DNA is in order. The 
DNAs of HSV-l and HSV-2 are linear double-stranded mole­
cules approximately 100 X 106 in molecular weight. They pos­
sess base compositions of 67 and 69 mol%, respectively, of 
G+C, and the distribution of bases is nonuniform. Herpes 
simplex virus DNA possesses alkali-labile interruptions that 
have been variously attributed to the presence of ribonucleo­
tides, single-stranded nicks, or gaps in the DNA. Whether the 
interruptions are positioned randomly or nonrandomly remains 
to be determined. Importantly for genetic analysis, isolated 
HSV DNA derived from virions and infected cells is infectious. 
The sequence arrangement of HSV DNA is unique among DNA 
viruses in that it consists of two covalently linked components, 
designated Land S, comprising 82% and 18%, respectively, of 
the viral genome (Fig 1). Each component consists of unique 
sequences (UL and Us) bracketed by inverted reiterated se­
quences. The reiterated sequences bracketing UL are designated 
ab and b' a', and each comprises 6% of the DNA; the reiterated 
sequences bracketing Us are designated a' c' and ca, and each 
comprises 4.3% of the total DNA. After digestion of terminal a 
sequences with processive nucleases, HSV DNA can circularize. 
Because the terminal reiterated sequences are inverted inter­
nally, Sheldrick and Berthelot [4J proposed that recombination 
between the terminal reiterated sequences and their inverted 
counterparts within the molecule could lead to inversion of the 
Land S components. That the Land S components can indeed 
invert relative to each other has been established unequivocally 
[5,6J. As a consequence of its ability to invert, virion-associated 
DNA consists of four equimolar populations of molecules dif­
fering only in the relative orientation of Land S. Cleavage of 
such preparations of HSV DNA with restriction endonucleases 
yields a series of unimolar fragments derived from unique 
sequences, half-molar fragments derived from molecular ter­
mini, and quarter-molar fragments derived from sequences that 
span the junction between Land S components. 
ISOLATION OF MUTANTS 
Most HSV mutants described to date have been derived by 
mutagenesis of replicating virus with bromodeoxyuridine 
(BUDR) or other mutagens that act on replicating DNA. Others 
have been isolated following mutagenesis of virions with nitrous 
acid (NA), hydroxylamine (HA), or nitrosoguanidine (NTG)­
mutagens that act on nonreplicating DNA. Although such 
42s 
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"brute force" mutagenesis procedures were necessary to estab­
lish the rudimentary genetic map of HSV, that map has now 
been established and emphasis has recently shifted to placing 
mutations into preselected regions of the viral genome. Despite 
the availability of a variety of procedures for introducing mu­
tations into individual bases within a viral DNA fragment 
whose base sequence is known, application of these procedures 
to the mutagenesis of HSV DNA awaits more extensive se­
quence data for specific regions of the viral genome. Nonethe­
less, in the absence of sequence data, it has been possible to 
introduce ts and other types of mutations into preselected 
regions of the viral genome, i.e., into individual viral DNA 
fragments. 
ts Mutants 
In order to introduce mutations into specific viral DNA 
fragments, the cloned or gel-purified fragment of choice is 
mutagenized in vitro with hydroxylamine or nitrous acid (Fig 
2, A). The mutagenized fragment is then mixed with intact 
infectious wild-type viral DNA, and the DNA mixture is copre­
cipitated with CaCIz. Cells are cotransfected with the precipi­
tated DNA preparation, and mutagenized fragments are intro­
duced into infectious wild-type viral DNA-presumably by 
homologous recombination-during synthesis of the infectious 
wild-type DNA. Progeny virus from cotransfected cultures are 
plated, and plaque isolates are screened for temperature sensi­
tivity at 34 and 39'C, the permissive and nonpermissive tem­
peratures for HSV ts mutants, or other markers. ts mutants 
isolated in this manner are then subjected to complementation 
analysis in order to determine the gene assignments of mutants 
(i.e., the number of genes represented by the group of mutants 
as a whole and the identity of mutants that are defective in the 
same gene) [3]. 
Mutants representing many of the 33 HSV -1 genes identified 
to date by complementation analysis have been mapped by 
marker rescue (Fig 2, B). Mapping ts mutations by marker 
rescue involves transfection of cells with CaClz-precipitated 
mixtures of infectious ts mutant DNA and individual wild-type 
viral DNA fragments [7]. If a ts mutation lies in sequences 
represented by a specific wild-type DNA fragment, the progeny 
of the transfection will contain ts+ recombinant virus as well 
as ts mutant virus generated by replication of infectious mutant 
DNA. Only ts virus (i.e., no ts+ recombinant virus) is generated 
by cotransfection of cells with ts mutant viral DNA and wild­
type DNA fragments in which the ts mutation does not lie. In 
this way, mutations can be mapped to sequences comprising 
only a few hundred base pairs. An example of marker rescue of 
a ts mutant, tsAl, is shown in Fig 3. 
In addition to ts mutants, mutants that render infected cells 
resistant to immune cytolysis and drug-resistant mutants have 
proven especially valuable for functional analysis of HSV genes. 
iCf ts Mutants 
HSV -1 and HSV -2 induce the synthesis of at least four major 
viral glycoproteins (gB, gC, gD, and gEl that have been shown 
to constitute the major inducers and targets of both humoral 
and cell-mediated immunity. All four glycoproteins are present 
in virion envelopes and on the surfaces of lytically infected 
cells in culture. As the major antigens in the induction of 
immunity to HSV, the presence of one or more of these glyco­
proteins on the surfaces of HSV -transformed and latently 
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FIG 2. A, Procedure for introduction of mutations into specific 
regions of the viral genome. B, Physical mapping of ts mutations by 
marker rescue. (Data from [7,8].) 
infected cells would suggest a role for the immune response in 
modulation of tumorigenesis and metastasis, as well as in 
reactivation of virus from the latent state. The evidence for the 
presence of viral glycoproteins on transformed cell surfaces and 
for viral antigens (probably glycoproteins) on the surfaces of 
latently infected cells is considerable. 
Given our relative ignorance of the specific functional roles 
of viral glycoproteins in virus replication, transformation, and 
latency, HSV mutants exhibiting altered synthesis or incorpo­
ration of glycoproteins into infected cell membranes should 
prove especially useful. Immune cytolysis-resistant tempera­
ture-sensitive (iCf ts) mutants constitute just such a class of 
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FIG 3. Results of marker rescue tests with tsAl. (From [9}.) 
mutants. Mutants that render the cells they infect resistant to 
cytolysis with glycoprotein-specific antibody and complement 
at 39°C but not at 34°C would, by definition, be expected to be 
defective in the synthesis or processing of individual viral 
glycoproteins or in other gene products required for synthesis 
and processing. 
ier ts mutants are selected in the following manner: First, 
viral DNA fragments containing the gene for an individual viral 
glycoprotein or genes involved in glycoprotein synthesis and/ 
or processing are mutagenized in vitro and reinserted into the 
wild-type viral genome by cotransfection with wild-type viral 
DNA as described above. Second, cells are infected with mu­
tagenized virus at a multiplicity of one infectious virus particle 
per cell. Third, infected cells are incubated at the nonpermissive 
temperature (39°C) for 12 h--the time required for viral gly­
cop rote ins to be synthesized--and inserted into surface mem­
branes. Fourth, infected cells are then treated with monospe­
cific antibody to a specific glycoprotein or glycoproteins and 
complement. This treatment lyses only cells expressing this 
(these) glycoprotein(s)--those cells infected with mutants de­
fective in glycoprotein synthesis, processing, or membrane in­
sertion would survive immune cytolysis. Fifth, surviving cells 
are washed and plated at 34°C, the permissive temperature. 
Sixth, plaques--derived from cells infected with ier ts mutant 
virus--are picked and amplified. And finally, ier ts mutants are 
then characterized biochemically in an effort to determine the 
nature of the defect that leads to failure to insert the particular 
glycoprotein into cell surface membranes resulting in cytolysis 
resistance at 39°C. 
Because they are ts for growth and plaque formation, ier ts 
mutants can be mapped on the viral genome in the same 
manner as ts mutants (Fig 2, B). 
The locations of a series of ts and ier ts mutants representing 
19 functional complementation groups are shown in Fig 4. It 
should be emphasized that the bars shown represent the limits 
of the viral DNA fragment in which a particular ts mutation 
lies and not the limits of the corresponding gene. Groups A-V 
were mapped using ts mutants, and groups W-Z were mapped 
using glycoprotein-deficient ier ts mutants. 
The map shown in Fig 4 not only illustrates the location of 
mutants in a specific functional group, but it also provides a 
basis for the rapid identification of mutants in new functional 
groups. Thus the physical map location of a new ts mutant is 
first determined and complementation analysis is then con­
ducted only with mutants that map in the same region of the 
genome. 
Drug-Resistant Mutants 
HSV-1 and HSV-2 encode a large number of enzymes re­
quired for viral DNA synthesis. These enzymes either are the 
targets of or are required for the processing of most of the 
available anti herpes drugs. Mutants that are resistant to these 
drugs by virtue of mutations in DNA synthetic enzymes can 
prove invaluable in (1) elucidating the mechanisms of action of 
antiviral drugs and (2) determining the functional properties 
of viral DNA synthetic enzymes. 
For these reasons, mutants resistant to a variety of antiviral 
drugs [including BUDR, acyclovir (ACV), phosphonoacetic acid 
(PAA), phosphonoformate (PFA), arabinosyladenine (araA), 5-
bromovinyldeoxyuridine (BVDU), and others] have been iso­
lated. 
Unlike ts and icr ts mutants, the isolation of drug-resistant 
mutants does not necessitate prior mutagenesis of viral DNA. 
Rather, spontaneously occurring mutants able to produce 
plaques in the presence of a given drug occur with measurable 
frequency in most stocks of wild-type viruses. These plaques 
are simply picked and replated several times in the presence of 
the drug. Because drug-resistance markers are readily detected 
on a background of drug-sensitive wild-type virus simply by 
plating in the presence of drug, these markers are mapped by 
the marker-transfer procedure. Here, individual fragments of 
mutant viral DNA are cotransfected with infectious wild-type 
viral DNA and the resulting progeny are plated in the presence 
of the appropriate drug. Drug-resistant plaques arise only after 
cotransfection with the mutant DNA fragment carrying, and 
therefore able to transfer, the drug-resistance marker. A phys­
ical map of drug-resistance markers in the HSV DNA poly­
merase gene will be presented below. 
Although other types of viral mutants exist (e.g., plaque 
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morphology and host-range mutants), ts, icr ts, and drug­
resistant mutants have proven especially useful as tools for 
determining the functions of specific viral genes. Examples of 
how each of these types of mutants has assisted in defining the 
roles of individual viral genes are presented below. Specifically, 
mutants in the major HSV DNA-binding protein (Fig 4, group 
A), a mutant in a late gene affecting glycosylation (Fig 4, group 
W), and mutants in the viral DNA polymerase gene (Fig 4, 
groups C, D, and 0) will be discussed. 
USES OF VIRAL MUTANTS 
ts Mutants: Definition of the Gene for the Major HSV-J DNA­
Binding Protein [9] 
The major DNA-binding protein, a polypeptide of approxi­
mately 130,000 daltons (130 K) belonging to the early kinetic 
class of viral gene products, was described first for HSV -1 by 
Bayliss et al [11) and subsequently for HSV-2 by Purifoy and 
Powell [12). To date, we know that the 130 K protein binds 
preferentially to single-stranded DNA, is required for HSV 
DNA synthesis [13], and may act to stabilize DNA polymerase 
activity [14). Interestingly, antisera prepared against HSV -l or 
HSV -2-infected cell proteins cross-react with DNA-binding 
proteins having approximate molecular weights of 130,000 in 
cells infected with bovine mamillitis virus, pseudorabies virus, 
and equine abortion virus, indicating that the gene for the 130 
K protein has been conserved evolutionarily [15,16). 
The map location of the 130 K protein was first suggested 
by the studies of Conley et a!., who isolated a DNA-negative 
temperature-sensitive mutant, tsHA1, that maps between co­
ordinates 0.385 and 0.402 [17). The smallest DNA fragment 
able to rescue tsHA1 selected an mRNA species from HSV-1-
infected cells which, when translated in vitro, encoded a poly­
peptide having a molecular weight of 128,000. The simplest 
explanation for these results is that the mutation in tsHA1 lies 
in or near the gene coding for the 130 K DNA-binding protein. 
It is interesting that the HSV-1 DNA fragment that rescued 
tsHAl (coordinates 0.385-0. 402) lies within the region of the 
HSV -1 genome that has been shown to induce morphologic 
transformation of mouse and hamster cells in vitro, suggesting 
a potential role for this protein in morphologic transformation. 
The availability of tsHA1 prompted complementation studies 
wtih this mutant and other DNA-negative early mutants [9). 
These studies demonstrated that tsHAl is a member of a larger 
group of 8 ts mutants of HSV -1 belonging to complementation 
group 1-l. Furthermore, members of group 1-1 fail to comple­
ment mutants in HSV-2 complementation group 2-2. 
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FIG 5. Map locations of temperature-sensitive mutants within the 
HSV -1 BglII I fragment and sequences immediately to the right of this 
fragment. ts1201 was described and mapped by Preston et al. [20]; 
tsJ12 and tsJ33 by N. DeLuca (personal communication); tsZ47 by 
Pancake et al [21]; tsAl, tsAl5, tsA42, tsAl6, and tsA24 by Weller et 
al [9]; and tsC7, tsC4, tsD9, ts022, and tsN20 by Coen et al [19]. 
The mutations of 5 other members of group 1-1 map in or 
near the sequence in which the tsHA1 mutation maps, a se­
quence that lies near the center of UL between the genes for 
the viral DNA polymerase and viral glycoprotein gB (Fig 5). 
These mutants can be divided into two groups; the mutations 
of one group (tsA1, tsA15, and tsA42) map between coordinates 
0.385 and 0.398, and the mutations of the other group (tsA16 
and tsA24) map between coordinates 0.398 and 0.413. At the 
non permissive temperature, mutants in group 1-1 are viral­
DNA-negative, and mutant-infected cells fail to react with 
monoclonal antibody to the 130 K DNA-binding protein. Taken 
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together, these data indicate that mutants in HSV -1 and HSV-
2 complementation groups 1-1 and 2-2, respectively, define the 
gene for the major HSV DNA-binding protein, an early gene 
product required for DNA synthesis. 
icr ts Mutants: An HSV-1 Gene Involved in a Late Stage of 
Glycoprotein Processing [ISJ 
tsW44, a DNA-positive (i.e., late) mutant of HSV-l, was 
selected for its ability to render cells resistant to immune 
cytolysis mediated by complement and monospecific rabbit 
antiserum to glycoprotein gB at 39.5°C but not at 34°C. 
The ts mutation in tsW44 was mapped by marker rescue to 
the EcoRI 0 fragment (Fig 4)-a 1.4-kb fragment that does not 
contain the coding sequences for any of the known viral gly­
coproteins. Cells infected with tsW 44 and labeled with p4C] 
glucosamine from 4-18 h at 39.5°C synthesized wild-type levels 
of gD but reduced levels of gB and gC. Importantly, wild-type 
levels of all viral glycoproteins were detected at 39.5°C in cells 
infected with ts+ revertants of tsW 44. 
Despite the reduced levels of synthesis of gB and gC in 
mutant-infected cells at 39.5°C, wild-type levels of 12·'I-labeled 
gB, gC, and gD were detected in plasma membranes of infected 
cells, implying that the small amounts of gB and gC synthesized 
were efficiently associated with the plasma membrane. 
Of interest was the resistance of tsW 44-infected cells at 
39.5°C to cytolysis mediated by complement and rabbit anti­
serum to gB, given that wild-type amounts of gB as well as gC 
and gD were present in plasma membranes of mutant-infected 
cells as measured by 12"I-labeling (cells infected with tsW44: 
94% survivors; wild-type virus: 15% survivors). Of greater 
interest, however, was the observation that mutant-infected 
cells at 39.5°C were also resistant to cytolysis mediated by 
complement and hyperimmune rabbit antiserum to HSV-in­
fected cells. This antiserum contains antibodies to all the major 
viral glycoproteins and their processive intermediates (cells 
infected with tsW 44: 94 % survivors; wild-type virus: 5% survi­
vors). 
Preliminary tests of the ability of lectins with specific car­
bohydrate-binding properties to bind to surfaces of wild-type 
virus and tsW44-infected cells at 39°C suggest a defect in the 
addition of galactose moieties to mutant glycoproteins. Taken 
together, these findings imply that (1) all mutant glycoproteins 
are either improperly glycosylated and/or improperly associ­
ated with plasma membranes, rendering them inaccessible to 
complement-binding antibody yet able to be labeled by 12fiI at 
the cell surface, and (2) a mutation in a single viral gene may 
be responsible for the altered glycosylation/insertion common 
to all mutant glycoproteins. 
Drug-Resistant Mutants: Fine Mapping and Molecular Cloning 
of Mutations in the Herpes Simplex Virus DNA Polymerase 
Locus [19J 
HSV induces a novel DNA polymerase activity that resem­
bles mammalian DNA polymerase a in several respects, yet 
can be distinguished from cellular polymerases by a variety of 
criteria, including sensitivity to certain antiviral drugs or their 
triphosphate derivatives. Considerable evidence indicates that 
HSV specifies this polymerase activity and that the activity is 
essential for viral replication. This evidence rests on studies of 
a variety of temperature-sensitive (ts) and drug-resistant mu­
tants of HSV that specify altered polymerase activities. Of 
these, the ts mutants have been assigned to three complemen­
tation groups (Fig 4, groups C, D, and 0). However, based on 
the close proximity of these groups on the physical map of the 
viral genome and the overlapping patterns of complementation 
displayed by several of them, they may be regarded as affecting 
one function, DNA polymerase (pol). 
The location of these polymerase mutants defines the pol 
locus, the precise limits of which remain unknown. One ap­
proach to defining these limits is to map mutations within the 
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pol locus precisely. By definition, the pol locus must at least 
span the distance between mutations within it. Based on pre­
vious studies, this would correspond to a distance of 0.7 kb. 
Several lines of evidence indicate that the HSV polymerase is 
a polypeptide of about 150,000 daltons; thus 0.7 kb would 
probably represent only a small fraction of the coding capacity 
of the pol locus. 
Similarly, the location of mutations in non-pol genes can 
provide limits beyond which the pol locus could not extend 
without overlapping these other genes. Thus mutations in 5 
phenotypically distant mutants derived from HSV -1, strain 
KOS, that lie in or near the HSV DNA polymerase (pol) locus 
were fine mapped with the aid of cloned fragments of mutant 
and wild-type viral DNAs to distinct restriction fragments of 
1.1 kb or less [19]. . 
DNA sequences containing a mutation or mutations confer­
ring resistance to the antiviral drugs phosphonoacetic acid 
(PAA), acyclovir (ACVl, and arabinosyladenine (araA) of pol 
mutant paa' -5 have been cloned as a 27 -kb Bgi II fragment in 
E. coli. These drug-resistance markers have been mapped more 
finely in marker-transfer experiments to a 1.1-kb fragment 
(coordinates 0.427-0.434) (Fig 6). In intratypic marker rescue 
experiments, ts, PAA-resistance, and ACV-resistance markers 
of pol mutant tsD9 have been mapped to a 0.8-kb fragment at 
the left end of the EcoRI M fragment (0.422-0.427). The ts 
mutation of pol mutant tsC4 maps within a 0.3-kb sequence 
(coordinates 0.420-0.422), while that of tsC7 lies within the 
1.1-kb fragment immediately to the left (coordinates 0.413-
0.420). tsC4 displays the novel phenotype of hypersensitivity 
to PAA; however, the PAA-hypersensitivity phenotype is al­
most certainly not due to the mutation(s) conferring tempera­
ture sensitivity. The ts mutation of mutant tsN20-which does 
not affect DNA polymerase activity-maps to a 0.5-kb frag­
ment at the right-hand end of the EcoRI M fragment (coordi­
nates 0.445-0.448). 
The mapping of the ts and drug-resistance mutations in these 
five mutants further defines the limits of the pol locus. More-
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FIG 6. Map locations of drug-resistant and temperature-sensitive 
mutants that define the functional limits of the HSV DNA polymerase 
gene. Innermost limits: 1.2 kb. The pol locus must span this distance. 
Outermost limits: 8 kb. The pol locus cannot extend beyond these limits 
without overlapping other genes. PAA'-l and PAA'-2 were mapped by 
Chartrand et al [22]. 
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over, these mutations, in all probability, affect different func­
tional sites on the polymerase molecule. The drug-resistance 
mutations should be especially useful in identifying such sites 
in that mutations conferring resistance to specific drugs should 
affect those functional sites which interact with the drug. For 
example, mutants resistant to the pyrophosphate analogue, 
phosphonoacetic acid (PAA) would be expected to specify pol­
ymerases affected in pyrophosphate exchange and release, while 
mutants resistant to acyclovir (ACV) or arabinosyladenine 
(araA), which are deoxyribose purine analogues altered in their 
sugar moieties, would be expected to specify polymerases af­
fected in sugar recognition at the deoxyribonucleoside trio­
phosphate binding site. The fine mapping of mutants differ­
entially affecting these functions should then aid in the corre­
lation of polymerase structure and function. 
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